US · TLRY
Tilray Brands, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Leamington, ON N8H 5L4
- Website
- tilray.com
Price · as of 2025-05-31
$6.16
Market cap 796.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $2.60 | -57.79% |
| Intrinsic Value(DCF) | $2.60 | -57.79% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $4.00 | $58.20 | |||
| 2017 | $1.60 | $34.90 | |||
| 2018 | $258.20 | $131.29 | $16,553.51 | $5.70 | $112.70 |
| 2019 | $425.70 | $257.44 | $1,613,691.07 | $5.10 | $0.00 |
| 2020 | $74.60 | $43.18 | $128,611.92 | $0.00 | $0.00 |
| 2021 | $144.20 | $125.23 | $0.00 | $0.00 | $0.00 |
| 2022 | $39.00 | $40.90 | $0.00 | $0.00 | $0.00 |
| 2023 | $26.20 | $12.21 | $0.00 | $0.00 | $0.00 |
| 2024 | $17.90 | $54.73 | $0.00 | $3.84 | $0.00 |
| 2025 | $6.50 | $2.60 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Tilray Brands, Inc.'s (TLRY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $2.60
- Current price
- $6.16
- AI upside
- -57.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.60
-57.79% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TLRY | Tilray Brands, Inc. | $6.16 | 796.82M | -58% | -58% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
| ALVO | Alvotech | $3.99 | 1.24B | +1,454% | +12% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| AMPH | Amphastar Pharmaceuticals… | $20.23 | 929.61M | +167% | -56% | -25% | -32% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| DVAX | Dynavax Technologies Corp… | $15.50 | 1.82B | +159% | -40% | -64% | -64% | 68.57 | 3.14 | 6.75 | 30.92 | — | 3.15 | 82.17% | -1.49% | 9.85% | 4.48% | -2.66% | 2.75% | 0.43 | -0.61 | 10.80 | 9.67 | 3.47 | -50323.00% | 1936.00% | -3763.00% | 3.21% | 0.85 | 43.90% | 0.00% | 0.00% | 5.34% | -342.86 | 23.49 | 5.10 | 2.81 |
| EVO | Evotec SE | $3.40 | 1.21B | +721% | -44% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| HROW | Harrow Health, Inc. | $54.18 | 2.01B | +502% | +346% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| IMNM | Immunome, Inc. | $21.86 | 2B | +132% | -83% | — | +492% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| MAZE | Maze Therapeutics, Inc. | $45.59 | 2.19B | — | -84% | -77% | — | 10.06 | 2.67 | 3.14 | 5.84 | — | 2.67 | 100.00% | 34.38% | 31.18% | 50.47% | 196.80% | 33.48% | 0.14 | — | 9.76 | 9.52 | -2.80 | -10339.00% | — | -18572.00% | 14.23% | 3.67 | 261.38% | 0.00% | 0.00% | 36.28% | 6.17 | 4.75 | 2.12 | 7.53 |
| NEOG | Neogen Corporation | $11.23 | 2.44B | +204% | -82% | — | — | -1.01 | 0.53 | 1.23 | -2.01 | -0.01 | -2.73 | 47.10% | 1.05% | -122.06% | -41.88% | 0.27% | -27.33% | 0.44 | 0.13 | 3.32 | 1.62 | -0.84 | 1146322.00% | -320.00% | -3914.00% | -4.21% | 0.33 | -1.38% | 0.00% | 0.00% | 0.00% | 200.15 | -40.68 | 2.11 | 0.67 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| PAHC | Phibro Animal Health Corp… | $54.59 | 2.21B | +18% | +113% | -92% | -25% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
About Tilray Brands, Inc.
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
- CEO
- Irwin David Simon
- Employees
- 2.65K
- Beta
- 2.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.60 ÷ $6.16) − 1 = -57.79% (DCF, example).